To evaluate various markers of renal function and bone density after the switch to Tenofovir
alafenamide fumarate (TAF) in chronic hepatitis B patients who are currently treated with
Tenofovir disoproxil fumarate (TDF) .
Phase:
Phase 4
Details
Lead Sponsor:
Asian Pacific Liver Center at St. Vincent Medical Center